Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21343591 | 0.91 | DPP4 (0.34) | PEPD | |
| SCHEMBL19658165 | 0.87 | PEPD (0.35) | PEPDSMN1; SMN2PIK3CD | |
| SCHEMBL18994149 | 0.84 | PEPD (0.33) | PEPDSMN1; SMN2 | |
| SCHEMBL22534979 | 0.80 | DPP4 (0.35) | PEPD | |
| SCHEMBL19658095 | 0.78 | PEPD (0.37) | PEPD | |
| SCHEMBL19772721 | 0.77 | — | — | |
| SCHEMBL11992649 | 0.77 | ATM (0.36) | PEPD | |
| SCHEMBL20348164 | 0.76 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL21142890 | 0.76 | MEN1 (0.46) | — | |
| SCHEMBL15033769 | 0.76 | PIK3CD (0.50) | PEPDSMN1; SMN2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | PEPD 389/4885SMN1; SMN2 1564/4885PIK3CD 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.